Tamanho Do Mercado De Medicamentos Para Câncer Uterino E Drivers De Crescimento Da Indústria Até 2030

Global Uterine Cancer Drug Market

Tamanho do mercado em biliões de dólares

CAGR : 8.50 %

Período de previsão	2023 –2030
Tamanho do mercado (ano base )	USD 2,412,036.20 Thousand
Tamanho do mercado ( Ano de previsão)	USD 4,269,049.34 Thousand
CAGR	8.50 %
Principais participantes do mercado	Baxter Accord BioPharma Eli Lilly and Company Hikma Pharmaceuticals PLC Sun Pharmaceutical Industries

>Mercado global de medicamentos para o cancro do útero, por tipo de cancro (cancro do endométrio e sarcoma uterino), tipo de tratamento (quimioterapia, hormonoterapia, terapia dirigida, imunoterapia e outros), tipo de medicamento (genérico e de marca), faixa etária ( adultos e geriátricos), Via de Administração (Oral e Parentérica), Utilizador Final (Hospitais, Centros Oncológicos, Clínicas Especializadas e Outros), Canal de Distribuição (Concurso Directo, Vendas a Retalho e Outros) - Tendências e Previsão do Sector para 2030.

Análise e insights do mercado de medicamentos contra o cancro uterino

O mercado global de medicamentos contra o cancro do útero é um segmento vital dentro da indústria farmacêutica oncológica mais ampla, refletindo a crescente prevalência de casos de cancro do útero em todo o mundo. O cancro do útero está entre as neoplasias ginecológicas mais comuns, com uma taxa de incidência que tem vindo a aumentar constantemente ao longo dos anos. Vários factores contribuem para esta tendência, incluindo o envelhecimento da população, a epidemia de obesidade e a melhoria das capacidades de diagnóstico, levando a uma detecção mais precoce. Como resultado, o mercado de medicamentos contra o cancro uterino continua a expandir-se à medida que as empresas farmacêuticas desenvolvem tratamentos inovadores para responder às necessidades dos doentes que enfrentam esta doença desafiante.

Os principais impulsionadores do mercado global de medicamentos contra o cancro do útero incluem os avanços na I&D, uma ênfase crescente na medicina de precisão e uma compreensão em evolução dos mecanismos moleculares que impulsionam o mercado.

No entanto, o mercado enfrenta desafios como o elevado custo associado ao custo do tratamento, a falta de pessoal qualificado e os requisitos regulamentares complexos.

Espera-se que o mercado global de medicamentos contra o cancro do útero ganhe crescimento de mercado no período de previsão de 2023 a 2030. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 8,5% no período de previsão de 2023 a 2030 e deverá atingir os 4.269.049,34 milhares de USD até 2030, contra 2.412.036,20 milhares de USD em 2022.

O relatório global do mercado de medicamentos contra o cancro do útero fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, o impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações de mercado, aprovações de produtos, decisões estratégicas, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado, contacte-nos para um resumo do analista. A nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir a meta desejada. A escalabilidade e expansão do negócio das unidades de retalho nos países em desenvolvimento de diversas regiões e a parceria com fornecedores para a distribuição segura de produtos de máquinas e medicamentos são os principais impulsionadores que impulsionaram a procura do mercado no período de previsão.

Métrica de relatório	Detalhes
Período de previsão	2023 a 2030
Ano base	2022
Anos históricos	2021 (personalizável para 2015-2020)
Unidades Quantitativas	Receita em mil dólares
Segmentos cobertos	Tipo de cancro (cancro do endométrio e sarcoma uterino), tipo de tratamento (quimioterapia, hormonoterapia, terapêutica dirigida, imunoterapia e outros), tipo de medicamento (genérico e de marca), faixa etária (adultos e geriátricos), via de administração ( oral e parentérica ), Utilizador Final (Hospitais, Centros Oncológicos, Clínicas Especializadas e Outros), Canal de Distribuição (Concurso Directo, Vendas a Retalho e Outros)
Países abrangidos	EUA, Canadá, México, Alemanha, França, Reino Unido, Itália, Espanha, Rússia, Turquia, Bélgica, Holanda, Suíça, resto da Europa, China, Japão, Índia, Austrália, Coreia do Sul, Nova Zelândia, Singapura, Tailândia, Filipinas, Malásia, Indonésia, resto da Ásia-Pacífico, Brasil, Argentina, resto da América do Sul, Arábia Saudita, Emirados Árabes Unidos, África do Sul, Egito, Qatar, Kuwait e resto do Médio Oriente e África
Participantes do mercado abrangidos	Baxter, Accord BioPharma, Inc., Eli Lilly and Company, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Fresenius SE & Co., Inc., GSK plc., Eisai Co., Ltd., Pfizer Inc., Virtus e Getwell Oncology, entre outros.

Definição global do mercado de medicamentos contra o cancro do útero

Os medicamentos contra o cancro do útero compreendem uma classe de medicamentos e terapias farmacêuticas especificamente concebidas para tratar e controlar o cancro do útero, uma doença maligna com origem no endométrio, o revestimento interno do útero. Estes medicamentos desempenham um papel crítico no tratamento e cuidados abrangentes de indivíduos com diagnóstico de cancro uterino. Os seus principais objetivos são atingir, suprimir ou eliminar as células cancerígenas dentro do útero, retardando ou parando assim a progressão da doença e reduzindo os sintomas associados, como hemorragia uterina anormal, dor pélvica e desconforto.

Dinâmica global do mercado de medicamentos contra o cancro uterino

Motoristas

Aumento da incidência de cancro uterino em todo o mundo

Nos últimos anos, o mundo tem assistido a um aumento notável da prevalência do cancro uterino, emergindo como um problema de saúde global significativo. A crescente incidência do cancro do útero em todo o mundo é uma questão complexa e multifacetada, influenciada por uma combinação de fatores genéticos, de estilo de vida, ambientais e de saúde.

Por exemplo,

Em março de 2023, de acordo com um artigo publicado pela Sociedade Americana de Oncologia Clínica (ASCO), o cancro do útero é o quarto cancro mais comum nas mulheres nos EUA. em 2020

Assim, a crescente incidência do cancro do útero em todo o mundo está a impulsionar o crescimento do mercado.

Avanços crescentes na terapêutica dirigida para o cancro uterino

Os avanços na terapêutica dirigida para o cancro do útero têm-se mostrado promissores na melhoria dos resultados do tratamento, na redução dos efeitos secundários e na melhoria da qualidade de vida dos doentes. A terapia dirigida é um tipo de tratamento do cancro que se concentra em moléculas ou vias específicas envolvidas no crescimento e disseminação das células cancerígenas, em vez de afetar amplamente as células que se dividem rapidamente, como na quimioterapia tradicional.

As terapias dirigidas são medicamentos concebidos para atingir alterações específicas nas células cancerígenas. Podem ser úteis para o cancro uterino avançado ou de alto risco.

Por exemplo,

O Lenvatinib (Lenvima) é um inibidor da quinase . Impede que os tumores formem novos vasos sanguíneos. Também tem como alvo proteínas nas células cancerígenas que as ajudam a crescer. Um médico pode utilizar Lenvima em combinação com Keytruda. Vem como uma cápsula oral que toma todos os dias.

Assim, os crescentes avanços na terapia dirigida para o cancro uterino estão a impulsionar o crescimento do mercado.

Oportunidade

Avanços no perfil genómico e descoberta de biomarcadores

Os avanços no perfil genómico e na descoberta de biomarcadores tiveram um impacto significativo no tratamento do cancro uterino, oferecendo uma abordagem mais direcionada e personalizada para a gestão da doença. O cancro do útero abrange uma variedade de subtipos, e estes avanços ajudaram a identificar variações genéticas e características moleculares específicas de cada subtipo, permitindo estratégias de tratamento mais eficazes.

Em conclusão, os avanços no perfil genómico e na descoberta de biomarcadores transformaram o panorama do tratamento do cancro do útero. Estes desenvolvimentos levaram a uma melhor compreensão das características genéticas e moleculares dos subtipos de cancro uterino, a opções de tratamento mais direcionadas e ao potencial para deteção precoce. É promissor para melhorar ainda mais os resultados dos doentes e expandir a gama de opções terapêuticas disponíveis para indivíduos com cancro do útero à medida que a investigação continua a evoluir neste campo. Assim, espera-se que os avanços no perfil genómico e na descoberta de biomarcadores atuem como uma oportunidade para o crescimento do mercado.

Desafios/Restrições

Elevado custo do tratamento do cancro uterino

O cancro do útero requer frequentemente tratamento multimodal, que pode incluir cirurgia, radioterapia, quimioterapia, terapia dirigida e hormonoterapia. As despesas combinadas destas várias modalidades de tratamento, juntamente com as estadias hospitalares, consultas e visitas de seguimento associadas, podem aumentar significativamente o custo global do tratamento. Os doentes com cancro do útero podem necessitar de hospitalização para cirurgias, quimioterapia ou radioterapia, levando a custos substanciais associados a internamentos hospitalares, despesas com salas de operações e cuidados hospitalares.

Assim, o elevado custo do tratamento do cancro do útero está a dificultar o crescimento do mercado.

Obstáculos regulamentares no mercado

The regulatory hurdles in the market are critical factors that shape the development, approval, and accessibility of new treatments. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others, are responsible for ensuring the safety, efficacy, and quality of drugs. These agencies set strict standards and guidelines that companies must adhere to during the drug development process.

In conclusion, the regulatory hurdles in the market are multifaceted and often prolonged.

Thus, regulatory hurdles in the market is expected to act as challenge for the market growth.

Recent Developments

In October 2023, Merck and Co., Inc. introduced effects from the Phase three KEYNOTE-A39 trial (additionally referred to as EV-302), which turned into carried out in collaboration with Seagen and Astellas, comparing KEYTRUDA, Merck’s anti-PD-1 therapy, plus Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate, as compared to chemotherapy (gemcitabine plus cisplatin or carboplatin) in sufferers with formerly untreated domestically superior or metastatic urothelial carcinoma. This will help the company to expand the application of its brand KEYTRUDA
In December 2022, Sanofi and Innate Pharma SA announced an expansion of their collaboration, with Sanofi licensing a Natural Killer (NK) cell engager program targeting B7H3 from Innate’s ANKETTM (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKETTM targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization. This collaboration will help to expand sanofi’s oncology portfolio in the global market

Global Uterine Cancer Drugs Market Scope

The global uterine cancer drugs market is categorized into five notable segments based on cancer type, treatment type, drug type, age group, route of administration, end-user, and distribution channel.The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Cancer Type

Endometrial Cancer
Uterine Sarcoma

On the basis of cancer type, the market is segmented into endometrial cancer and uterine sarcoma.

Treatment Type

Chemotherapy
Immunotherapy
Hormone Therapy
Targeted Therapy
Others

On the basis of treatment type, the market is segmented into chemotherapy, immunotherapy, hormone therapy, targeted therapy, and others.

Drug Type

Generics
Branded

On the basis of drug type, the market is segmented into generics and branded.

Age Group

Geriatric
Adults

On the basis of age group, the market is segmented into geriatric and adults.

Route of Administration

Parenteral
Oral

On the basis of route of administration, the market is segmented into parenteral and oral.

End-User

Hospitals
Cancer Centers
Specialty Clinics
Others

On the basis of end-user, the market is segmented into hospitals, cancer centers, specialty clinics, and others.

Distribution Channel

Direct Tender
Retail Sales
Others

On the basis of distribution channel, the global uterine cancer drug market is segmented into direct tender, retail sales, and others.

Regional Analysis/Insights: Global Uterine Cancer Drugs Market

The global uterine cancer drugs market is categorized into seven notable segments such as cancer type, treatment type, drug type, age group, route of administration, end-user, and distribution channel.

The countries covered in this market report U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, and rest of Middle East And Africa.

The U.S. is expected to dominate the North America region due to the rise in technological advancement in uterine cancer drugs products market. Germany is expected to dominate the Europe region due to the strong presence of key players. China is expected to dominate the Asia-Pacific region due to the mass production of uterine cancer drugs based products and increasing demand from emerging markets and expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Share Analysis: Global Uterine Cancer Drugs Market

Global uterine cancer drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, product type lifeline curve. The above data points provided are only related to the company’s focus on the Global Uterine Cancer Drugs market.

Alguns dos principais players que operam no mercado global de medicamentos contra o cancro do útero são a Baxter, a Accord BioPharma, Inc., a Eli Lilly and Company, a Hikma Pharmaceuticals PLC, a Sun Pharmaceutical Industries Ltd., a Fresenius SE & Co. Teva Pharmaceuticals USA, Inc. , Amneal Pharmaceuticals LLC, Merck & Co., Inc., GSK plc., Eisai Co., Ltd., Pfizer Inc., Virtus e Getwell Oncology, entre outros.

SKU-50353

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Click on image to enlarge

Painel interativo de análise de dados
Painel de análise da empresa para oportunidades de elevado potencial de crescimento
Acesso de analista de pesquisa para personalização e customização. consultas
Análise da concorrência com painel interativo
Últimas notícias, atualizações e atualizações Análise de tendências
Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência

Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL UTERINE CANCER DRUGS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 CANCER TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL'S MODEL

4.2 PORTER'S 5 FORCES

4.3 EPIDEMIOLOGY

5 GLOBAL UTERINE CANCER DRUGS MARKET, REGULATORY FRAMEWORK

5.1 OVERVIEW

5.2 REGULATION IN THE U.S.

5.3 REGULATION IN CANADA

5.4 REGULATION IN EUROPE

5.5 REGULATION IN CHINA

5.6 REGULATION IN JAPAN

5.7 REGULATION IN AUSTRALIA

5.8 REGULATION IN INDIA

5.9 REGULATION IN BRAZIL

5.1 REGULATION IN SOUTH AFRICA

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING INCIDENCE OF UTERINE CANCER WORLDWIDE

6.1.2 GROWING ADVANCEMENTS IN TARGETED THERAPY FOR UTERINE CANCER

6.1.3 RISING AWARENESS OF UTERINE CANCER

6.1.4 RISING COLLABORATIONS AND PARTNERSHIPS AMONG LEADING PLAYERS

6.2 RESTRAINTS

6.2.1 HIGH COST OF UTERINE CANCER TREATMENT

6.2.2 SIDE EFFECTS AND TOXICITY ASSOCIATED WITH CANCER DRUGS

6.3 OPPORTUNITIES

6.3.1 ADVANCEMENTS IN GENOMIC PROFILING AND BIOMARKER DISCOVERY

6.3.2 GROWING R&D ACTIVITIES FOR UTERINE CANCER TREATMENT

6.4 CHALLENGES

6.4.1 REGULATORY HURDLES IN THE UTERINE CANCER DRUGS MARKET

6.4.2 DRUG RESISTANCE IN THE TREATMENT OF UTERINE CANCER

7 GLOBAL UTERINE CANCER DRUGS MARKET, BY CANCER TYPE

7.1 OVERVIEW

7.2 ENDOMETRIAL CANCER

7.2.1 UTERINE CARCINOSARCOMA

7.2.2 SEROUS ADENOSARCOMA

7.2.3 ADENOSQUAMOUS CARCINOMA

7.2.4 OTHER

7.3 UTERINE SARCOMA

7.3.1 UTERINE LEIOMYOSARCOMA

7.3.2 ENDOMETRIAL STROMAL SARCOMAS

7.3.3 UNDIFFERENTIATED SARCOMA

8 GLOBAL UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE

8.1 OVERVIEW

8.2 CHEMOTHERAPY

8.2.1 PACLITAXEL

8.2.2 CARBOPLATIN

8.2.3 CISPLATIN

8.2.4 DOXORUBICIN

8.2.5 DOCETAXEL

8.2.6 OTHERS

8.3 IMMUNOTHERAPY

8.4 HORMONE THERAPY

8.4.1 PROGESTINS

8.4.1.1 MEDROXYPROGESTERONE ACETATE

8.4.1.2 OTHERS

8.4.2 AROMATASE INHIBITORS

8.4.2.1 LETRAZOLE

8.4.2.2 ANASTRAZOLE

8.4.2.3 EXEMESTANE

8.4.3 LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS

8.4.3.1 GOSERELIN

8.4.3.2 LEUPROLIDE

8.4.4 OTHERS

8.5 TARGETED THERAPY

8.5.1 LENVATINAB

8.5.2 BEVACIZUMAB

8.5.3 MTOR INHIBITORS

8.5.3.1 EVEROLIMUS

8.5.3.2 TEMSIROLIMUS

8.6 OTHERS

9 GLOBAL UTERINE CANCER DRUGS MARKET, BY DRUG TYPE

9.1 OVERVIEW

9.2 GENERICS

9.3 BRANDED

9.3.1 KEYTRUDA

9.3.2 LENVIMA

9.3.3 PROVERA

9.3.4 TEMODAR

9.3.5 JEMPERLI

9.3.6 OTHERS

10 GLOBAL UTERINE CANCER DRUGS MARKET, BY AGE GROUP

10.1 OVERVIEW

10.2 GERIATRIC

10.3 ADULTS

11 GLOBAL UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 PARENTERAL

11.3 ORAL

12 GLOBAL UTERINE CANCER DRUGS MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITALS

12.2.1 PRIVATE

12.2.2 PUBLIC

12.3 CANCER CENTERS

12.4 SPECIALTY CLINICS

12.5 OTHERS

13 GLOBAL UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 RETAIL SALES

13.3.1 HOSPITAL PHARMACY

13.3.2 RETAIL PHARMACY

13.3.3 ONLINE PHARMACY

13.4 OTHERS

14 GLOBAL UTERINE CANCER DRUGS MARKET, BY REGION

14.1 OVERVIEW

14.2 NORTH AMERICA

14.2.1 U.S.

14.2.2 CANADA

14.2.3 MEXICO

14.3 EUROPE

14.3.1 GERMANY

14.3.2 U.K.

14.3.3 FRANCE

14.3.4 RUSSIA

14.3.5 ITALY

14.3.6 SPAIN

14.3.7 TURKEY

14.3.8 BELGIUM

14.3.9 NETHERLANDS

14.3.10 SWITZERLAND

14.3.11 REST OF EUROPE

14.4 ASIA-PACIFIC

14.4.1 CHINA

14.4.2 JAPAN

14.4.3 INDIA

14.4.4 AUSTRALIA

14.4.5 SOUTH KOREA

14.4.6 NEW ZEALAND

14.4.7 SINGAPORE

14.4.8 THAILAND

14.4.9 MALAYSIA

14.4.10 INDONESIA

14.4.11 PHILIPPINES

14.4.12 REST OF ASIA-PACIFIC

14.5 SOUTH AMERICA

14.5.1 BRAZIL

14.5.2 ARGENTINA

14.5.3 REST OF SOUTH AMERICA

14.6 MIDDLE EAST AND AFRICA

14.6.1 SAUDI ARABIA

14.6.2 U.A.E.

14.6.3 SOUTH AFRICA

14.6.4 EGYPT

14.6.5 KUWAIT

14.6.6 REST OF MIDDLE EAST AFRICA

15 GLOBAL UTERINE CANCER DRUGS MARKET, COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: GLOBAL

15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

15.3 COMPANY SHARE ANALYSIS: EUROPE

15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

16 SWOT ANALYSIS

17 COMPANY PROFILES

17.1 MERCK & CO., INC.

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENT

17.2 EISAI CO., LTD.

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENT

17.2.6 RECENT DEVELOPMENT

17.3 SANOFI

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENT

17.4 PFIZER INC.

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENT

17.5 TEVA PHARMACEUTICALS USA, INC.

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 PRODUCT PORTFOLIO

17.5.4 RECENT DEVELOPMENT

17.6 ACCORD HEALTHCARE US.

17.6.1 COMPANY SNAPSHOT

17.6.2 PRODUCT PORTFOLIO

17.6.3 RECENT DEVELOPMENT

17.7 AMNEAL PHARMACEUTICALS LLC

17.7.1 COMPANY SNAPSHOT

17.7.2 REVENUE ANALYSIS

17.7.3 PRODUCT PORTFOLIO

17.7.4 RECENT DEVELOPMENT

17.8 BAXTER

17.8.1 COMPANY SNAPSHOT

17.8.2 REVENUE ANALYSIS

17.8.3 COMPANY SHARE ANALYSIS

17.8.4 PRODUCT PORTFOLIO

17.8.5 RECENT DEVELOPMENT

17.9 ELI LILLY AND COMPANY

17.9.1 COMPANY SNAPSHOT

17.9.2 REVENUE ANALYSIS

17.9.3 PRODUCT PORTFOLIO

17.9.4 RECENT DEVELOPMENT

17.1 GETWELL ONCOLOGY

17.10.1 COMPANY SNAPSHOT

17.10.2 PRODUCT PORTFOLIO

17.10.3 RECENT DEVELOPMENT

17.11 GSK PLC.

17.11.1 COMPANY SNAPSHOT

17.11.2 REVENUE ANALYSIS

17.11.3 PRODUCT PORTFOLIO

17.11.4 RECENT DEVELOPMENT

17.12 HIKMA PHARMACEUTICALS PLC

17.12.1 COMPANY SNAPSHOT

17.12.2 REVENUE ANALYSIS

17.12.3 PRODUCT PORTFOLIO

17.12.4 RECENT DEVELOPMENT

17.13 SUN PHARMACEUTICAL INDUSTRIES LTD.

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENT

17.14 VIATRIS INC.

17.14.1 COMPANY SNAPSHOT

17.14.2 REVENUE ANALYSIS

17.14.3 PRODUCT PORTFOLIO

17.14.4 RECENT DEVELOPMENT

17.15 VIRTUS

17.15.1 COMPANY SNAPSHOT

17.15.2 PRODUCT PORTFOLIO

17.15.3 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

Lista de Tabela

TABLE 1 GLOBAL UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2022-2030 (USD THOUSAND)

TABLE 2 GLOBAL ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 3 GLOBAL ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 4 GLOBAL UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 5 GLOBAL UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 6 GLOBAL UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 7 GLOBAL CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 8 GLOBAL CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 9 GLOBAL IMMUNOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 10 GLOBAL HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 11 GLOBAL HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 12 GLOBAL PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 13 GLOBAL AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 14 GLOBAL LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 15 GLOBAL TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 16 GLOBAL TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 17 GLOBAL MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 18 GLOBAL OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 19 GLOBAL UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 20 GLOBAL GENERICS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 21 GLOBAL BRANDED IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 22 GLOBAL BRANDED IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 23 GLOBAL UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2022-2030 (USD THOUSAND)

TABLE 24 GLOBAL GERIATRIC IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 25 GLOBAL ADULTS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 26 GLOBAL UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 27 GLOBAL PARENTERAL IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 28 GLOBAL ORAL IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 29 GLOBAL UTERINE CANCER DRUGS MARKET, BY END USER, 2022-2030 (USD THOUSAND)

TABLE 30 GLOBAL HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 31 GLOBAL HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 32 GLOBAL CANCER CENTERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 33 GLOBAL SPECIALTY CLINICS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 34 GLOBAL OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 35 GLOBAL UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD THOUSAND)

TABLE 36 GLOBAL DIRECT TENDER IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 37 GLOBAL RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 38 GLOBAL RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 39 GLOBAL OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 40 GLOBAL UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 41 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 42 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 43 NORTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 44 NORTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 45 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 46 NORTH AMERICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 47 NORTH AMERICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 48 NORTH AMERICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 49 NORTH AMERICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 50 NORTH AMERICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 51 NORTH AMERICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 52 NORTH AMERICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 53 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 54 NORTH AMERICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 55 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 56 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 57 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 58 NORTH AMERICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 59 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 60 NORTH AMERICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 61 U.S. UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 62 U.S. ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 63 U.S. UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 64 U.S. UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 65 U.S. CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 66 U.S. HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 67 U.S. PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 68 U.S. AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 69 U.S. LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 70 U.S. TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 71 U.S. MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 72 U.S. UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 73 U.S. BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 74 U.S. UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 75 U.S. UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 76 U.S. UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 77 U.S. HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 78 U.S. UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 79 U.S. RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 80 CANADA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 81 CANADA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 82 CANADA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 83 CANADA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 84 CANADA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 85 CANADA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 86 CANADA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 87 CANADA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 88 CANADA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 89 CANADA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 90 CANADA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 91 CANADA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 92 CANADA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 93 CANADA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 94 CANADA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 95 CANADA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 96 CANADA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 97 CANADA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 98 CANADA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 99 MEXICO UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 100 MEXICO ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 101 MEXICO UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 102 MEXICO UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 103 MEXICO CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 104 MEXICO HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 105 MEXICO PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 106 MEXICO AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 107 MEXICO LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 108 MEXICO TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 109 MEXICO MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 110 MEXICO UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 111 MEXICO BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 112 MEXICO UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 113 MEXICO UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 114 MEXICO UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 115 MEXICO HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 116 MEXICO UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 117 MEXICO RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 118 EUROPE UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 119 EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 120 EUROPE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 121 EUROPE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 122 EUROPE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 123 EUROPE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 124 EUROPE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 125 EUROPE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 126 EUROPE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 127 EUROPE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 128 EUROPE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 129 EUROPE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 130 EUROPE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 131 EUROPE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 132 EUROPE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 133 EUROPE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 134 EUROPE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 135 EUROPE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 136 EUROPE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 137 EUROPE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 138 GERMANY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 139 GERMANY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 140 GERMANY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 141 GERMANY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 142 GERMANY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 143 GERMANY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 144 GERMANY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 145 GERMANY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 146 GERMANY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 147 GERMANY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 148 GERMANY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 149 GERMANY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 150 GERMANY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 151 GERMANY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 152 GERMANY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 153 GERMANY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 154 GERMANY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 155 GERMANY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 156 GERMANY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 157 U.K. UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 158 U.K. ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 159 U.K. UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 160 U.K. UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 161 U.K. CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 162 U.K. HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 163 U.K. PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 164 U.K. AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 165 U.K. LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 166 U.K. TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 167 U.K. MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 168 U.K. UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 169 U.K. BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 170 U.K. UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 171 U.K. UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 172 U.K. UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 173 U.K. HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 174 U.K. UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 175 U.K. RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 176 FRANCE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 177 FRANCE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 178 FRANCE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 179 FRANCE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 180 FRANCE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 181 FRANCE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 182 FRANCE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 183 FRANCE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 184 FRANCE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 185 FRANCE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 186 FRANCE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 187 FRANCE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 188 FRANCE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 189 FRANCE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 190 FRANCE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 191 FRANCE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 192 FRANCE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 193 FRANCE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 194 FRANCE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 195 RUSSIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 196 RUSSIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 197 RUSSIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 198 RUSSIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 199 RUSSIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 200 RUSSIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 201 RUSSIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 202 RUSSIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 203 RUSSIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 204 RUSSIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 205 RUSSIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 206 RUSSIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 207 RUSSIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 208 RUSSIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 209 RUSSIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 210 RUSSIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 211 RUSSIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 212 RUSSIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 213 RUSSIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 214 ITALY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 215 ITALY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 216 ITALY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 217 ITALY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 218 ITALY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 219 ITALY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 220 ITALY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 221 ITALY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 222 ITALY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 223 ITALY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 224 ITALY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 225 ITALY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 226 ITALY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 227 ITALY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 228 ITALY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 229 ITALY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 230 ITALY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 231 ITALY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 232 ITALY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 233 SPAIN UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 234 SPAIN ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 235 SPAIN UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 236 SPAIN UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 237 SPAIN CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 238 SPAIN HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 239 SPAIN PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 240 SPAIN AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 241 SPAIN LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 242 SPAIN TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 243 SPAIN MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 244 SPAIN UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 245 SPAIN BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 246 SPAIN UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 247 SPAIN UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 248 SPAIN UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 249 SPAIN HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 250 SPAIN UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 251 SPAIN RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 252 TURKEY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 253 TURKEY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 254 TURKEY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 255 TURKEY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 256 TURKEY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 257 TURKEY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 258 TURKEY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 259 TURKEY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 260 TURKEY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 261 TURKEY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 262 TURKEY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 263 TURKEY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 264 TURKEY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 265 TURKEY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 266 TURKEY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 267 TURKEY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 268 TURKEY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 269 TURKEY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 270 TURKEY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 271 BELGIUM UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 272 BELGIUM ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 273 BELGIUM UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 274 BELGIUM UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 275 BELGIUM CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 276 BELGIUM HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 277 BELGIUM PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 278 BELGIUM AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 279 BELGIUM LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 280 BELGIUM TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 281 BELGIUM MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 282 BELGIUM UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 283 BELGIUM BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 284 BELGIUM UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 285 BELGIUM UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 286 BELGIUM UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 287 BELGIUM HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 288 BELGIUM UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 289 BELGIUM RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 290 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 291 NETHERLANDS ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 292 NETHERLANDS UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 293 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 294 NETHERLANDS CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 295 NETHERLANDS HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 296 NETHERLANDS PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 297 NETHERLANDS AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 298 NETHERLANDS LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 299 NETHERLANDS TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 300 NETHERLANDS MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 301 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 302 NETHERLANDS BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 303 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 304 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 305 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 306 NETHERLANDS HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 307 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 308 NETHERLANDS RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 309 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 310 SWITZERLAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 311 SWITZERLAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 312 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 313 SWITZERLAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 314 SWITZERLAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 315 SWITZERLAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 316 SWITZERLAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 317 SWITZERLAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 318 SWITZERLAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 319 SWITZERLAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 320 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 321 SWITZERLAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 322 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 323 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 324 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 325 SWITZERLAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 326 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 327 SWITZERLAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 328 REST OF EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 329 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 330 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 331 ASIA-PACIFIC ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 332 ASIA-PACIFIC UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 333 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 334 ASIA-PACIFIC CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 335 ASIA-PACIFIC HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 336 ASIA-PACIFIC PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 337 ASIA-PACIFIC AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 338 ASIA-PACIFIC LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 339 ASIA-PACIFIC TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 340 ASIA-PACIFIC MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 341 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 342 ASIA-PACIFIC BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 343 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 344 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 345 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 346 ASIA-PACIFIC HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 347 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 348 ASIA-PACIFIC RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 349 CHINA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 350 CHINA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 351 CHINA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 352 CHINA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 353 CHINA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 354 CHINA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 355 CHINA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 356 CHINA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 357 CHINA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 358 CHINA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 359 CHINA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 360 CHINA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 361 CHINA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 362 CHINA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 363 CHINA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 364 CHINA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 365 CHINA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 366 CHINA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 367 CHINA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 368 JAPAN UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 369 JAPAN ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 370 JAPAN UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 371 JAPAN UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 372 JAPAN CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 373 JAPAN HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 374 JAPAN PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 375 JAPAN AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 376 JAPAN LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 377 JAPAN TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 378 JAPAN MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 379 JAPAN UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 380 JAPAN BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 381 JAPAN UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 382 JAPAN UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 383 JAPAN UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 384 JAPAN HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 385 JAPAN UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 386 JAPAN RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 387 INDIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 388 INDIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 389 INDIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 390 INDIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 391 INDIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 392 INDIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 393 INDIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 394 INDIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 395 INDIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 396 INDIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 397 INDIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 398 INDIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 399 INDIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 400 INDIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 401 INDIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 402 INDIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 403 INDIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 404 INDIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 405 INDIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 406 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 407 AUSTRALIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 408 AUSTRALIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 409 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 410 AUSTRALIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 411 AUSTRALIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 412 AUSTRALIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 413 AUSTRALIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 414 AUSTRALIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 415 AUSTRALIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 416 AUSTRALIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 417 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 418 AUSTRALIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 419 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 420 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 421 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 422 AUSTRALIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 423 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 424 AUSTRALIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 425 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 426 SOUTH KOREA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 427 SOUTH KOREA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 428 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 429 SOUTH KOREA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 430 SOUTH KOREA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 431 SOUTH KOREA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 432 SOUTH KOREA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 433 SOUTH KOREA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 434 SOUTH KOREA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 435 SOUTH KOREA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 436 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 437 SOUTH KOREA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 438 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 439 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 440 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 441 SOUTH KOREA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 442 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 443 SOUTH KOREA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 444 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 445 NEW ZEALAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 446 NEW ZEALAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 447 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 448 NEW ZEALAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 449 NEW ZEALAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 450 NEW ZEALAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 451 NEW ZEALAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 452 NEW ZEALAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 453 NEW ZEALAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 454 NEW ZEALAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 455 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 456 NEW ZEALAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 457 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 458 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 459 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 460 NEW ZEALAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 461 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 462 NEW ZEALAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 463 SINGAPORE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 464 SINGAPORE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 465 SINGAPORE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 466 SINGAPORE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 467 SINGAPORE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 468 SINGAPORE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 469 SINGAPORE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 470 SINGAPORE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 471 SINGAPORE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 472 SINGAPORE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 473 SINGAPORE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 474 SINGAPORE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 475 SINGAPORE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 476 SINGAPORE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 477 SINGAPORE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 478 SINGAPORE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 479 SINGAPORE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 480 SINGAPORE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 481 SINGAPORE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 482 THAILAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 483 THAILAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 484 THAILAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 485 THAILAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 486 THAILAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 487 THAILAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 488 THAILAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 489 THAILAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 490 THAILAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 491 THAILAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 492 THAILAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 493 THAILAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 494 THAILAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 495 THAILAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 496 THAILAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 497 THAILAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 498 THAILAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 499 THAILAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 500 THAILAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 501 MALAYSIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 502 MALAYSIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 503 MALAYSIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 504 MALAYSIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 505 MALAYSIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 506 MALAYSIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 507 MALAYSIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 508 MALAYSIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 509 MALAYSIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 510 MALAYSIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 511 MALAYSIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 512 MALAYSIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 513 MALAYSIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 514 MALAYSIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 515 MALAYSIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 516 MALAYSIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 517 MALAYSIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 518 MALAYSIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 519 MALAYSIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 520 INDONESIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 521 INDONESIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 522 INDONESIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 523 INDONESIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 524 INDONESIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 525 INDONESIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 526 INDONESIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 527 INDONESIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 528 INDONESIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 529 INDONESIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 530 INDONESIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 531 INDONESIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 532 INDONESIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 533 INDONESIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 534 INDONESIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 535 INDONESIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 536 INDONESIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 537 INDONESIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 538 INDONESIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 539 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 540 PHILIPPINES ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 541 PHILIPPINES UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 542 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 543 PHILIPPINES CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 544 PHILIPPINES HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 545 PHILIPPINES PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 546 PHILIPPINES AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 547 PHILIPPINES LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 548 PHILIPPINES TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 549 PHILIPPINES MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 550 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 551 PHILIPPINES BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 552 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 553 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 554 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 555 PHILIPPINES HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 556 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 557 PHILIPPINES RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 558 REST OF ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 559 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 560 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 561 SOUTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 562 SOUTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 563 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 564 SOUTH AMERICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 565 SOUTH AMERICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 566 SOUTH AMERICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 567 SOUTH AMERICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 568 SOUTH AMERICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 569 SOUTH AMERICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 570 SOUTH AMERICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 571 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 572 SOUTH AMERICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 573 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 574 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 575 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 576 SOUTH AMERICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 577 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 578 SOUTH AMERICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 579 BRAZIL UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 580 BRAZIL ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 581 BRAZIL UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 582 BRAZIL UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 583 BRAZIL CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 584 BRAZIL HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 585 BRAZIL PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 586 BRAZIL AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 587 BRAZIL LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 588 BRAZIL TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 589 BRAZIL MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 590 BRAZIL UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 591 BRAZIL BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 592 BRAZIL UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 593 BRAZIL UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 594 BRAZIL UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 595 BRAZIL HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 596 BRAZIL UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 597 BRAZIL RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 598 ARGENTINA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 599 ARGENTINA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 600 ARGENTINA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 601 ARGENTINA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 602 ARGENTINA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 603 ARGENTINA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 604 ARGENTINA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 605 ARGENTINA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 606 ARGENTINA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 607 ARGENTINA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 608 ARGENTINA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 609 ARGENTINA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 610 ARGENTINA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 611 ARGENTINA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 612 ARGENTINA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 613 ARGENTINA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 614 ARGENTINA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 615 ARGENTINA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 616 ARGENTINA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 617 REST OF SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 618 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 619 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 620 MIDDLE EAST AND AFRICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 621 MIDDLE EAST AND AFRICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 622 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 623 MIDDLE EAST AND AFRICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 624 MIDDLE EAST AND AFRICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 625 MIDDLE EAST AND AFRICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 626 MIDDLE EAST AND AFRICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 627 MIDDLE EAST AND AFRICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 628 MIDDLE EAST AND AFRICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 629 MIDDLE EAST AND AFRICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 630 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 631 MIDDLE EAST AND AFRICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 632 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 633 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 634 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 635 MIDDLE EAST AND AFRICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 636 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 637 MIDDLE EAST AND AFRICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 638 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 639 SAUDI ARABIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 640 SAUDI ARABIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 641 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 642 SAUDI ARABIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 643 SAUDI ARABIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 644 SAUDI ARABIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 645 SAUDI ARABIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 646 SAUDI ARABIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 647 SAUDI ARABIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 648 SAUDI ARABIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 649 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 650 SAUDI ARABIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 651 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 652 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 653 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 654 SAUDI ARABIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 655 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 656 SAUDI ARABIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 657 U.A.E. UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 658 U.A.E. ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 659 U.A.E. UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 660 U.A.E. UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 661 U.A.E. CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 662 U.A.E. HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 663 U.A.E. PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 664 U.A.E. AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 665 U.A.E. LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 666 U.A.E. TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 667 U.A.E. MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 668 U.A.E. UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 669 U.A.E. BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 670 U.A.E. UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 671 U.A.E. UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 672 U.A.E. UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 673 U.A.E. HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 674 U.A.E. UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 675 U.A.E. RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 676 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 677 SOUTH AFRICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 678 SOUTH AFRICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 679 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 680 SOUTH AFRICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 681 SOUTH AFRICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 682 SOUTH AFRICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 683 SOUTH AFRICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 684 SOUTH AFRICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 685 SOUTH AFRICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 686 SOUTH AFRICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 687 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 688 SOUTH AFRICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 689 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 690 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 691 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 692 SOUTH AFRICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 693 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 694 SOUTH AFRICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 695 EGYPT UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 696 EGYPT ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 697 EGYPT UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 698 EGYPT UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 699 EGYPT CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 700 EGYPT HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 701 EGYPT PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 702 EGYPT AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 703 EGYPT LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 704 EGYPT TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 705 EGYPT MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 706 EGYPT UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 707 EGYPT BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 708 GYPT UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 709 EGYPT UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 710 EGYPT UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 711 EGYPT HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 712 EGYPT UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 713 EGYPT RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 714 KUWAIT UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 715 KUWAIT ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 716 KUWAIT UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 717 KUWAIT UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 718 KUWAIT CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 719 KUWAIT HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 720 KUWAIT PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 721 KUWAIT AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 722 KUWAIT LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 723 KUWAIT TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 724 KUWAIT MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 725 KUWAIT UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 726 KUWAIT BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 727 KUWAIT UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 728 KUWAIT UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 729 KUWAIT UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 730 KUWAIT HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 731 KUWAIT UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 732 KUWAIT RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 733 REST OF MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

Lista de Figura

FIGURE 1 GLOBAL UTERINE CANCER DRUGS MARKET: SEGMENTATION

FIGURE 2 GLOBAL UTERINE CANCER DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL UTERINE CANCER DRUGS MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL UTERINE CANCER DRUGS MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL UTERINE CANCER DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL UTERINE CANCER DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL UTERINE CANCER DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL UTERINE CANCER DRUGS MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 GLOBAL UTERINE CANCER DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL UTERINE CANCER DRUGS MARKET: SEGMENTATION

FIGURE 11 RISING INCIDENCE OF UTERINE CANCER IS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 12 ENDOMETRIAL CANCER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 AND 2030

FIGURE 13 NORTH AMEIRCA IS EXPECTED TO DOMINATE THE GLOBAL UTERINE CANCER DRUGS MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR UTERINE CANCER DRUG MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL UTERINE CANCER DRUGS MARKET

FIGURE 16 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2022

FIGURE 17 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2023-2030 (USD THOUSAND)

FIGURE 18 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, CAGR (2023-2030)

FIGURE 19 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 20 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2022

FIGURE 21 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)

FIGURE 22 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, CAGR (2023-2030)

FIGURE 23 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 24 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2022

FIGURE 25 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND)

FIGURE 26 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030)

FIGURE 27 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 28 GLOBAL UTERINE CANCER DRUGS MARKET: BY TYPE, 2022

FIGURE 29 GLOBAL UTERINE CANCER DRUGS MARKET: BY AGE GROUP, 2023-2030 (USD THOUSAND)

FIGURE 30 GLOBAL UTERINE CANCER DRUGS MARKET: BY AGE GROUP, CAGR (2023-2030)

FIGURE 31 GLOBAL UTERINE CANCER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 32 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022

FIGURE 33 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)

FIGURE 34 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 35 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 36 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, 2022

FIGURE 37 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 38 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 39 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 40 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 41 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 42 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 43 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 44 GLOBAL UTERINE CANCER DRUGS MARKET: SNAPSHOT (2022)

FIGURE 45 GLOBAL UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)

FIGURE 46 NORTH AMERICA UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)

FIGURE 47 EUROPE UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)

FIGURE 48 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)

View Detailed Information

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

What are the primary segments covered in the Global Uterine Cancer Drug Market report?

The market is segmented based on Global Uterine Cancer Drugs Market, By Cancer Type (Endometrial Cancer and Uterine Sarcoma), Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy, and Others), Drug Type (Generic and Branded), Age Group (Adults and Geriatric), Route of Administration (Oral and Parenteral), End User (Hospitals, Cancer Centers, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2030. .

What is the current market size of the Global Uterine Cancer Drug Market?

The Global Uterine Cancer Drug Market size was valued at USD 2412036.20 USD Thousand in 2022.

What is the expected growth rate of the Global Uterine Cancer Drug Market?

The Global Uterine Cancer Drug Market is projected to grow at a CAGR of 8.5% during the forecast period of 2023 to 2030.

Who are the key players in the Global Uterine Cancer Drug Market?

The major players operating in the market include Baxter, Accord BioPharma, Eli Lilly and Company, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries , Fresenius SE & Co. KGaA, Viatris , Sanofi, Teva Pharmaceuticals USA, Amneal Pharmaceuticals LLC, Merck & Co., GSK plc., Eisai Co., Pfizer , Virtus, Getwell Oncology.

Which countries are analyzed in the Global Uterine Cancer Drug Market report?

The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, and rest of Middle East And Africa.

Mercado global de medicamentos para o cancro do útero – Tendências do setor e previsão para 2030

Mercado global de medicamentos para o cancro do útero – Tendências do setor e previsão para 2030

Global Uterine Cancer Drug Market

CAGR : 8.50 %

Análise e insights do mercado de medicamentos contra o cancro uterino

Definição global do mercado de medicamentos contra o cancro do útero

Dinâmica global do mercado de medicamentos contra o cancro uterino

Global Uterine Cancer Drugs Market Scope

Regional Analysis/Insights: Global Uterine Cancer Drugs Market

Competitive Landscape and Share Analysis: Global Uterine Cancer Drugs Market

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

Relatórios

Informações de mercado

Apoiar

Soluções

Mercado global de medicamentos para o cancro do útero – Tendências do setor e previsão para 2030

Mercado global de medicamentos para o cancro do útero – Tendências do setor e previsão para 2030

Global Uterine Cancer Drug Market

CAGR : 8.50 %

Análise e insights do mercado de medicamentos contra o cancro uterino

Definição global do mercado de medicamentos contra o cancro do útero

Dinâmica global do mercado de medicamentos contra o cancro uterino

Global Uterine Cancer Drugs Market Scope

Regional Analysis/Insights: Global Uterine Cancer Drugs Market

Competitive Landscape and Share Analysis: Global Uterine Cancer Drugs Market

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

Navegue pelas páginas relacionadas